ENDRA Life Sciences Long-Term Debt 2011-2026 | NDRA

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt ENDRA Life Sciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
363 K	487 K	-	366 K	547 K	337 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
547 K	337 K	420 K

Quarterly Long-Term Debt ENDRA Life Sciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
397 K	429 K	461 K	487 K	-	98.4 K	-	192 K	237 K	281 K	324 K	366 K	434 K	473 K	510 K	547 K	553 K	586 K	252 K	272 K	290 K	272 K	272 K	343 K	343 K	343 K	343 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
586 K	98.4 K	364 K

Long-Term Debt of other stocks in the Diagnostics research industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
Koninklijke Philips N.V. PHG	5.7 B	$ 29.7	3.74 %	$ 20 B	Niderland
Centogene N.V. CNTG	15.6 M	-	-6.23 %	$ 30.6 M	Germany
Agilent Technologies A	2.73 B	$ 121.87	3.06 %	$ 37 B	USA
Burning Rock Biotech Limited BNR	18.3 M	$ 20.67	-8.13 %	$ 222 M	China
Accelerate Diagnostics AXDX	782 K	-	-61.36 %	$ 2.46 M	USA
Aspira Women's Health AWH	1.04 M	-	-6.19 %	$ 10.5 M	USA
Biocept BIOC	1.2 M	-	-13.05 %	$ 7.29 M	USA
Chembio Diagnostics CEMI	76.7 K	-	0.22 %	$ 16.8 M	USA
CareDx, Inc CDNA	19.7 M	$ 21.42	-4.46 %	$ 1.14 B	USA
Oxford Immunotec Global PLC OXFD	32 K	-	-	$ 562 M	Britain
DermTech DMTK	38 K	-	-11.32 %	$ 2.94 M	USA
Akumin AKU	1.25 B	-	-17.87 %	$ 25.9 M	Canada
Enzo Biochem ENZ	189 K	-	-8.98 %	$ 14.8 K	USA
Co-Diagnostics CODX	574 K	$ 1.56	6.85 %	$ 2.08 M	USA
Exact Sciences Corporation EXAS	6.4 M	-	-	$ 19.8 B	USA
Castle Biosciences CSTL	9.74 M	$ 25.05	2.0 %	$ 696 M	USA
Global Cord Blood Corporation CO	147 K	-	-	$ 399 M	China
Fluidigm Corporation FLDM	54.2 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	388 K	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	5.49 M	-	0.12 %	$ 80.1 M	China
Charles River Laboratories International CRL	2.14 B	$ 183.88	3.92 %	$ 9.11 B	USA
PRA Health Sciences, Inc. PRAH	1.16 B	-	-	$ 10.7 B	USA
Danaher Corporation DHR	18.4 B	$ 194.75	0.5 %	$ 139 B	USA
Interpace Biosciences IDXG	752 K	$ 2.0	-9.09 %	$ 8.85 M	USA
Myriad Genetics MYGN	120 M	$ 5.08	1.6 %	$ 470 M	USA
Heska Corporation HSKA	307 K	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	546 K	-	-20.0 %	$ 1.06 M	USA
NeoGenomics NEO	342 M	$ 8.35	2.33 %	$ 1.07 B	USA
Neogen Corporation NEOG	875 M	$ 9.51	2.92 %	$ 2.06 B	USA
Medpace Holdings MEDP	114 M	$ 520.6	0.96 %	$ 15 B	USA
Illumina ILMN	554 M	$ 134.5	1.34 %	$ 21.4 B	USA
Precipio PRPO	47 K	$ 28.3	-2.41 %	$ 45.4 M	USA
Fulgent Genetics FLGT	360 K	$ 16.26	0.81 %	$ 492 M	USA
Guardant Health GH	1.5 B	$ 90.36	5.44 %	$ 11.3 B	USA
Senseonics Holdings SENS	35.6 M	$ 6.77	-	$ 282 M	USA
QIAGEN N.V. QGEN	1.65 B	-	-	$ 10.6 B	Niderland
Anixa Biosciences ANIX	163 K	$ 2.91	2.83 %	$ 94.4 K	USA
Soleno Therapeutics SLNO	49.9 M	$ 52.78	0.4 %	$ 2.68 B	USA
Biomerica BMRA	100 K	$ 2.18	-0.91 %	$ 5.01 M	USA
Motus GI Holdings MOTS	1.24 M	-	-34.28 %	$ 263 K	Israel
ICON Public Limited Company ICLR	3.4 B	$ 119.68	3.55 %	$ 9.87 B	Irlanda
Laboratory Corporation of America Holdings LH	5.08 B	$ 270.68	1.62 %	$ 22.5 B	USA
Neuronetics STIM	65.8 M	$ 1.42	1.43 %	$ 93.7 M	USA
Celcuity CELC	138 M	$ 122.46	-2.23 %	$ 5.73 B	USA
Lantheus Holdings LNTH	569 M	$ 83.82	-0.12 %	$ 5.66 B	USA
Thermo Fisher Scientific TMO	39.2 B	$ 526.6	2.05 %	$ 199 B	USA
Trinity Biotech plc TRIB	82.7 M	$ 0.75	6.62 %	$ 61.9 M	Irlanda
Quest Diagnostics Incorporated DGX	5.17 B	$ 195.02	1.86 %	$ 21.6 B	USA